<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020774</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068712</org_study_id>
    <secondary_id>UCLA-0002038</secondary_id>
    <secondary_id>NCI-G01-1958</secondary_id>
    <nct_id>NCT00020774</nct_id>
  </id_info>
  <brief_title>SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer</brief_title>
  <official_title>A Phase IB Clinical Study Of The Farnesyltransferase Inhibitor SCH 66336 And Gemcitabine In Patients With Resectable Primary Liver Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of SCH 66336 with or without&#xD;
      gemcitabine followed by surgery with that of surgery alone in treating patients who have&#xD;
      primary liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the biologic activity and toxicity of neoadjuvant SCH 66336 with or&#xD;
      without gemcitabine followed by surgical resection vs surgical resection alone in patients&#xD;
      with resectable primary liver cancer.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study. Patients are randomized to one of three&#xD;
      treatment arms. Arm I: Patients receive neoadjuvant oral SCH 66336 twice daily for 14 days&#xD;
      followed by surgical resection. Arm II: Patients receive neoadjuvant oral SCH 66336 twice&#xD;
      daily for 14 days and gemcitabine IV over 30 minutes once weekly for 2 weeks followed by&#xD;
      surgical resection. Arm III: Patients undergo surgical resection. Patients receive no&#xD;
      neoadjuvant therapy prior to resection.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30 patients (10 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed resectable primary hepatocellular carcinoma&#xD;
             or cholangiocarcinoma&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  Hematopoietic: Absolute neutrophil count greater than 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN) SGOT or SGPT no greater&#xD;
             than 5 times ULN&#xD;
&#xD;
          -  Albumin at least 2.5 g/dL INR less than 1.3 Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Cardiovascular: QTc prolongation no greater than 440 msec Other:&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 6 weeks since prior surgery and recovered&#xD;
&#xD;
          -  At least 6 weeks since prior systemic therapy and recovered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic disease outside of the liver&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  malabsorption or other gastrointestinal (GI) condition that would preclude ability to&#xD;
             take oral medication and/or GI absorption (e.g., partial small bowel obstruction)&#xD;
&#xD;
          -  non-malignant systemic disease that would preclude study&#xD;
&#xD;
          -  active uncontrolled infection No grade II nausea or grade I vomiting despite&#xD;
             antiemetic medication&#xD;
&#xD;
          -  concurrent immunotherapy Chemotherapy: No other concurrent chemotherapy&#xD;
&#xD;
          -  concurrent hormonal therapy including estrogen therapy&#xD;
&#xD;
          -  concurrent oral contraceptives or other hormonal methods Concurrent megestrol acetate&#xD;
             allowed&#xD;
&#xD;
          -  concurrent corticosteroids (except for nausea/vomiting during gemcitabine&#xD;
             administration)&#xD;
&#xD;
          -  concurrent CYP3A4 inhibitors or inducers including: Azoles (e.g., itraconazole,&#xD;
             clotrimazole, fluconazole, or ketoconazole) Macrolide antibiotics (e.g., azithromycin,&#xD;
             clarithromycin, or erythromycin) Cyclosporine Grapefruit Antiepileptic medication&#xD;
             (e.g., phenytoin, carbamazepine, or phenobarbital) Antibiotics for tuberculosis (e.g.,&#xD;
             rifampin or isoniazid)&#xD;
&#xD;
          -  concurrent HIV protease inhibitors (e.g., amprenavir, ritonavir, or saquinavir&#xD;
             mesylate)&#xD;
&#xD;
          -  concurrent cisapride&#xD;
&#xD;
          -  other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael G. Amado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>April 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2004</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>adult primary cholangiocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

